TBIO - Translate Bio, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
8.88
+0.15 (+1.72%)
As of 1:53PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close8.73
Open8.63
Bid8.66 x 2200
Ask8.90 x 800
Day's Range8.55 - 9.22
52 Week Range5.00 - 16.60
Volume34,556
Avg. Volume92,071
Market Cap400.862M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-7.01
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est25.00
Trade prices are not sourced from all markets
  • The Wall Street Journal7 days ago

    [$$] Moderna IPO Marks Milestone for New Biotech Market

    Inc.’s $604.3 million initial public offering is a highlight in a big year for the new field of messenger-RNA therapeutics. Moderna, whose drugs and vaccines are designed to cause cells to produce molecules that treat or prevent disease, went public at $23 a share late Thursday and began trading Friday at $22. Alnylam, valued at $7.38 billion, this year became the first to win U.S. approval for a product in a class of treatments, known as siRNA therapy, which silence disease-causing RNA molecules.

  • GlobeNewswire10 days ago

    Translate Bio Expands Patent Portfolio with Newly Issued U.S. Patent Relating to Its Messenger RNA (mRNA) Therapeutics Platform (MRT™)

    Translate Bio (TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent 10,143,758.  This patent titled “Liver Specific Delivery of Messenger RNA” builds on the Company’s 2009 patent filing relating to liposomal delivery of therapeutic mRNA to the liver, enhancing the Company’s current intellectual property by providing additional coverage for core delivery capabilities. This patent is owned by Translate Bio and provides protection until March, 2032.

  • Do Institutions Own Shares In Translate Bio Inc (NASDAQ:TBIO)?
    Simply Wall St.21 days ago

    Do Institutions Own Shares In Translate Bio Inc (NASDAQ:TBIO)?

    If you want to know who really controls Translate Bio Inc (NASDAQ:TBIO), then you’ll have to look at the makeup of its share registry. Institutions will often hold stock in Read More...

  • GlobeNewswirelast month

    Translate Bio Announces Third Quarter 2018 Financial Results and Reviews Recent Highlights

    Continued progress with ongoing Phase 1/2 clinical trial in CF and towards IND submission for OTC Deficiency LEXINGTON, Mass., Nov. 08, 2018 -- Translate Bio (Nasdaq: TBIO), a.

  • GlobeNewswirelast month

    Translate Bio to Participate in Upcoming Investor Conferences

    LEXINGTON, Mass., Nov. 01, 2018 -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially.

  • GlobeNewswire2 months ago

    Translate Bio to Present Preclinical Data Supporting MRT5005 at the 32nd Annual North American Cystic Fibrosis Conference

    Translate Bio, Inc. (TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced the presentation of preclinical data for MRT5005, a first-in-class mRNA therapeutic designed to treat all patients with cystic fibrosis regardless of mutation. The presentation includes data demonstrating that MRT5005 was efficiently delivered to the lungs of rodents and non-human primates by nebulization, resulting in functional cystic fibrosis transmembrane conductance regulator (CFTR) protein expression.

  • GlobeNewswire3 months ago

    Translate Bio to Participate in the Leerink Partners Roundtable Series: Rare Disease & Oncology

    LEXINGTON, Mass., Sept. 25, 2018-- Translate Bio, a clinical-stage messenger RNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein ...

  • Benzinga5 months ago

    Leerink: Translate Bio's Cystic Fibrosis Candidate Could Generate $1.8B

    Leerink sees potential in Translate Bio Inc  (NASDAQ: TBIO ) mRNA-based candidate for cystic fibrosis patients with Class I mutations. The Analyst Leerink's Geoffrey Porges initiated coverage of  Translate ...

  • Benzinga5 months ago

    Translate Bio's Novel mRNA Therapy Candidate Addresses A Key Investor Concern, Citi Says

    Translate Bio Inc (NASDAQ: TBIO ) went public by offering 9.35 million shares. The offering was priced at $13 per share on June 28. The Analyst With the IPO quiet period expiring, Credit Suisse analyst ...

  • Business Wire6 months ago

    Translate Bio Announces Pricing of Initial Public Offering

    Translate Bio, Inc. a clinical-stage messenger RNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced the pricing of its initial public offering of 9,350,000 shares of its common stock at a price to the public of $13.00 per share, for total gross proceeds of approximately $121.6 million, before ...

  • Benzinga6 months ago

    The IPO Outlook For The Week: Shipping, Medtech, Mobility And Retail

    For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . Hyrecar Inc. (NASDAQ: HYRE ) will issue 2 million shares between $5 and $6 Wednesday on the Nasdaq. The firm facilitates ...